Table 4.

Univariate analysis of prognostic factors for 147 patients.

Variate	5-Year survival rate (%)
	OS	P	LRRFS	P	DMFS	P	DFS	P
Age, years		0.927		0.809		0.878		0.823
≤17	88.5		96.8		84.6		81.9
>17	88.7		94.3		84.9		80.9
Gender		0.816		0.657		0.443		0.786
Male	89.2		95.8		83.4		81.2
Female	87.6		93.4		89.0		82.7
Pretreatment BMI, kg/m2		0.634		0.347		0.846		0.895
<23	88.3		94.5		85.0		81.3
≥23	92.9		100		83.6		83.6
T stage		0.008		0.317		0.002		<0.001
T1–T3	97.2		97.3		94.6		93.2
T4	80.2		92.6		74.7		69.4
N stage		0.629		0.829		0.585		0.540
N0–1	90.4		93.9		88.0		84.6
N2–3	88.1		95.7		83.5		80.3
Pretreatment EBV DNA, copies/mL		0.193		0.099		0.003		<0.001
≤40,000	91.5		96.8		89.1		86.9
>40,000	81.2		89.4		70.6		63.9
Combination with chemotherapy		0.632		0.751		0.252		0.318
No	100.0		100.0		66.7		66.7
Yes	88.5		95.1		85.2		81.9
Total dose of cisplatin, mg/m2		0.601		0.874		0.640		0.980
<320	87.8		94.6		85.2		80.3
≥320	89.6		95.6		84.2		82.5

BMI, body mass index; OS, overall survival; LRRFS, locoregional relapse-free survival; DMFS, distant metastasis-free survival; DFS, disease-free survival.